Join BIOCYTOGEN at Biotech Showcase 2025
We’re thrilled to announce our participation as an exhibitor at Biotech Showcase 2025! Taking place from January 13th to 15th in San Francisco, California, this premier investor conference is a pivotal platform for private and micro-to-mid-cap biotechnology companies to showcase their groundbreaking innovations. With unmatched opportunities for one-to-one engagements, Biotech Showcase connects these trailblazers directly with investors and biopharmaceutical executives, fostering collaboration and driving life science advancements.
What is Biotech Showcase 2025?
Biotech Showcase is a dedicated investor conference designed to provide private and micro-mid-cap biotechnology companies with the opportunity to present to and connect with investors and biopharmaceutical executives. With a roster of over 400 carefully selected presenting companies from across the globe, ranging from seed-stage startups to established multinational corporations, encompassing diverse fields such as platform technologies, therapeutic areas, digital health, devices, and diagnostics, these events attract investors wielding over USD 400 billion in capital and motivated strategic partners within the life science ecosystem.
Event Overview
Date: January 13th 8:00 am – 15th 5:15 pm
Location: Hilton San Francisco Union Square. 333 O’Farrell Street | San Francisco, CA 94102
Event Schedule
The Biotech Showcase 2025 in San Francisco, California will showcase a diverse array of speakers and topics. For a comprehensive look at the daily schedule, including session times and detailed information on each presentation, please refer to the Biotech Showcase 2025 agenda.
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We look forward to seeing you at the Biotech Showcase 2025 in San Francisco, CA!
